Login to Your Account



NeurogesX Shares Slump on Missed Endpoint for Pain Patch

By Donna Young


Friday, February 29, 2008
Shares of NeurogesX Inc. plunged Thursday after the firm said a confirmatory Phase III study of its capsaicin dermal patch NGX-4010 missed its primary endpoint of providing statistically significant benefit in treating peripheral neuropathic pain in patients with HIV infection. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription